Tags

Type your tag names separated by a space and hit enter

Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
Curr Med Res Opin. 2019 03; 35(3):461-472.CM

Abstract

OBJECTIVE

Severe diarrhea-predominant irritable bowel syndrome (IBS-D) is associated with decreased health-related quality of life (HRQOL) and increased health care costs. Treatment recommendations for IBS-D often start with traditional pharmacotherapy (TP), with escalation to alosetron, rifaximin or eluxadoline if there is no success. There has been no previous head-to-head clinical trial comparing IBS-D treatment outcome for alosetron versus TP. This study, GSK protocol S3B30020, evaluated resource use, work productivity, health-related quality of life and global symptom response in women with IBS-D who were treated with alosetron or TP.

METHODS

A total of 1956 patients who met criteria for severe IBS-D were randomized to treatment with alosetron 1 mg twice daily (BID) or only TP for up to 24 weeks. Work productivity and resource use were evaluated by standard questionnaires, HRQOL by the IBSQOL instrument and IBS symptoms by the Global Improvement Scale (GIS).

RESULTS

Compared to only TP, alosetron-treated patients reported: (1) fewer clinic/office visits for any health problem (p = .0181) or for IBS-D (p = .0004); (2) reduced use of over-the-counter medications for IBS-D (p < .0001); (3) fewer days of lost work productivity (p < .0001); (4) decreased restriction of social and outdoor activities (p < .0001); and (5) greater global improvement in IBS-D symptoms (p < .0001). Alosetron treatment improved HRQOL scores for all domains (p < .0001). Incidence of adverse events during alosetron use was not remarkable and was similar to that previously reported.

CONCLUSIONS

Alosetron 1 mg BID significantly reduced health care utilization and lost productivity, and significantly improved global IBS symptoms, HRQOL, and participation in outdoor and social activities compared with treatment response to TP.

Authors+Show Affiliations

a Department of Medicine , St Joseph's Hospital and Medical Center , Phoenix , AZ , USA.b Division of Gastroenterology , University of Michigan Health System , Ann Arbor , MI , USA.c Prometheus Laboratories Inc. , San Diego , CA , USA.c Prometheus Laboratories Inc. , San Diego , CA , USA.c Prometheus Laboratories Inc. , San Diego , CA , USA.c Prometheus Laboratories Inc. , San Diego , CA , USA.

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30293448

Citation

Olden, Kevin W., et al. "Alosetron Versus Traditional Pharmacotherapy in Clinical Practice: Effects On Resource Use, Health-related Quality of Life, Safety and Symptom Improvement in Women With Severe Diarrhea-predominant Irritable Bowel Syndrome." Current Medical Research and Opinion, vol. 35, no. 3, 2019, pp. 461-472.
Olden KW, Chey WD, Shringarpure R, et al. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Curr Med Res Opin. 2019;35(3):461-472.
Olden, K. W., Chey, W. D., Shringarpure, R., Paul Nicandro, J., Chuang, E., & Earnest, D. L. (2019). Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Current Medical Research and Opinion, 35(3), 461-472. https://doi.org/10.1080/03007995.2018.1533456
Olden KW, et al. Alosetron Versus Traditional Pharmacotherapy in Clinical Practice: Effects On Resource Use, Health-related Quality of Life, Safety and Symptom Improvement in Women With Severe Diarrhea-predominant Irritable Bowel Syndrome. Curr Med Res Opin. 2019;35(3):461-472. PubMed PMID: 30293448.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. AU - Olden,Kevin W, AU - Chey,William D, AU - Shringarpure,Reshma, AU - Paul Nicandro,Jean, AU - Chuang,Emil, AU - Earnest,David L, Y1 - 2018/11/22/ PY - 2018/10/9/pubmed PY - 2018/10/9/medline PY - 2018/10/9/entrez KW - Alosetron versus traditional therapy KW - quality of life KW - severe diarrhea-predominant irritable bowel syndrome KW - symptom improvement KW - work productivity SP - 461 EP - 472 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 35 IS - 3 N2 - OBJECTIVE: Severe diarrhea-predominant irritable bowel syndrome (IBS-D) is associated with decreased health-related quality of life (HRQOL) and increased health care costs. Treatment recommendations for IBS-D often start with traditional pharmacotherapy (TP), with escalation to alosetron, rifaximin or eluxadoline if there is no success. There has been no previous head-to-head clinical trial comparing IBS-D treatment outcome for alosetron versus TP. This study, GSK protocol S3B30020, evaluated resource use, work productivity, health-related quality of life and global symptom response in women with IBS-D who were treated with alosetron or TP. METHODS: A total of 1956 patients who met criteria for severe IBS-D were randomized to treatment with alosetron 1 mg twice daily (BID) or only TP for up to 24 weeks. Work productivity and resource use were evaluated by standard questionnaires, HRQOL by the IBSQOL instrument and IBS symptoms by the Global Improvement Scale (GIS). RESULTS: Compared to only TP, alosetron-treated patients reported: (1) fewer clinic/office visits for any health problem (p = .0181) or for IBS-D (p = .0004); (2) reduced use of over-the-counter medications for IBS-D (p < .0001); (3) fewer days of lost work productivity (p < .0001); (4) decreased restriction of social and outdoor activities (p < .0001); and (5) greater global improvement in IBS-D symptoms (p < .0001). Alosetron treatment improved HRQOL scores for all domains (p < .0001). Incidence of adverse events during alosetron use was not remarkable and was similar to that previously reported. CONCLUSIONS: Alosetron 1 mg BID significantly reduced health care utilization and lost productivity, and significantly improved global IBS symptoms, HRQOL, and participation in outdoor and social activities compared with treatment response to TP. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/30293448/Alosetron_versus_traditional_pharmacotherapy_in_clinical_practice:_effects_on_resource_use_health_related_quality_of_life_safety_and_symptom_improvement_in_women_with_severe_diarrhea_predominant_irritable_bowel_syndrome_ L2 - http://www.tandfonline.com/doi/full/10.1080/03007995.2018.1533456 DB - PRIME DP - Unbound Medicine ER -